The estimated Net Worth of Sanjay Subramanian is at least $655 mil dollars as of 19 April 2022. Mr Subramanian owns over 27,100 units of Ocugen Inc stock worth over $33,333 and over the last 5 years he sold OCGN stock worth over $110,700. In addition, he makes $511,153 as Chief Accounting Officer, CFO, Treasurer y Head of Corp. Devel. & Corp. Sec. at Ocugen Inc.
Mr has made over 11 trades of the Ocugen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 27,100 units of OCGN stock worth $99,999 on 19 April 2022.
The largest trade he's ever made was exercising 35,591 units of Ocugen Inc stock on 29 January 2021 worth over $18,151. On average, Mr trades about 10,080 units every 42 days since 2019. As of 19 April 2022 he still owns at least 27,100 units of Ocugen Inc stock.
You can see the complete history of Mr Subramanian stock trades at the bottom of the page.
Sanjay S. Subramanian M.B.A. is the Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec. at Ocugen Inc.
As the Chief Accounting Officer, CFO, Treasurer y Head of Corp. Devel. & Corp. Sec. of Ocugen Inc, the total compensation of Mr A at Ocugen Inc is $511,153. There are 2 executives at Ocugen Inc getting paid more, with Dr. Shankar Musunuri M.B.A., MBA, Ph.D. having the highest compensation of $780,673.
Mr A is 45, he's been the Chief Accounting Officer, CFO, Treasurer y Head of Corp. Devel. & Corp. Sec. of Ocugen Inc since . There are 13 older and 3 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.
Sanjay's mailing address filed with the SEC is C/O INOZYME PHARMA, INC., 321 SUMMER STREET SUITE 400, BOSTON, MA, 02210.
Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang y Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Ocugen Inc executives and other stock owners filed with the SEC include: